林德斯健康与蒂芬巴赫集团启动临床试验以推进ME/CFS研究与治疗-动脉网

Lindus Health and Tiefenbacher Group Launching Clinical Trial to Advance ME/CFS Research and Treatment

CISION 等信源发布 2025-03-06 21:00



可切换为仅中文







BOSTON

波士顿

，

March 6, 2025

2025年3月6日

/PRNewswire/ --

Lindus Health

林达斯健康

, the 'anti-CRO' running radically faster, more reliable clinical trials, and

，‘反CRO’运行速度更快、更可靠的临床试验，以及

Tiefenbacher Group

蒂芬巴赫集团

, a leading healthcare company providing best-in-class solutions along the entire pharmaceutical value chain, have announced their collaboration on a clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

，一家领先的医疗保健公司，提供覆盖整个制药价值链的一流解决方案，宣布了他们在肌痛性脑脊髓炎/慢性疲劳综合症（ME/CFS）临床试验上的合作。

ME/CFS

is a long-term condition characterized by extreme fatigue, decreased cognitive function ('brain fog'), and other symptoms related to pain and dizziness. It is a relatively common condition that affects approximately 1% of the population. Despite its prevalence and impact on quality of life, ME/CFS remains poorly understood, with a critical shortage of effective treatment options for patients..

是一种以极度疲劳、认知功能下降（“脑雾”）、以及与疼痛和头晕相关的其他症状为特征的长期病症。这是一种相对常见的疾病，大约影响人口的1%。尽管其普遍性和对生活质量的影响，ME/CFS仍然未被充分理解，患者面临有效治疗选择严重不足的问题。

This Phase 2 trial,

这项二期试验，

ReMEdi

再教育

, will evaluate the efficacy of a therapeutic with proven success to treat symptoms of other fatigue-related conditions.

，将评估一种对治疗其他疲劳相关症状有成功效果的疗法的疗效。

ReMEdi

will adopt a virtual trial model, making it easier for patients with ME/CFS to complete study activities while offering a flexible, patient-centric solution for participation. Recruitment will be conducted primarily through social media advertising, with pre-screening facilitated through Lindus Health's home-grown eClinical technology, Citrus™.

将采用虚拟试验模式，使ME/CFS患者更容易完成研究活动，同时为参与提供灵活的、以患者为中心的解决方案。招募工作将主要通过社交媒体广告进行，初步筛选则通过Lindus Health自家开发的电子临床技术Citrus™来实现。

The platform will also be utilized to streamline data capture through electronic patient reported outcomes (ePROs) and carry out telehealth visits with the study team. Participants will be required to wear the .

该平台还将用于通过电子患者报告结果（ePRO）简化数据收集，并与研究团队进行远程医疗访问。参与者将被要求佩戴。

Oura ring

我们的戒指

for continuous remote monitoring and use the

用于持续远程监控和使用

GripAble

device for hand grip testing.

用于手握力测试的设备。

'Symptoms of ME/CFS can drastically diminish quality of life, and we're humbled to have the opportunity to contribute to Tiefenbacher's efforts to rewrite the narrative for this patient population,' said

“ME/CFS的症状可能会严重影响生活质量，我们很谦卑能够有机会为蒂芬巴赫公司为这一患者群体改写故事的努力做出贡献，”

Meri Beckwith

梅里·贝克沃斯

, co-founder of Lindus Health. 'By leveraging our virtual site services and eClinical platform, we're making participation more accessible while ensuring the collection of high-quality data to propel ME/CFS research.'

林德斯健康公司的联合创始人表示：“通过利用我们的虚拟站点服务和电子临床平台，我们正在使参与更加便捷，同时确保收集高质量数据以推动ME/CFS研究。”

'ME/CFS can be incredibly debilitating, keeping people from doing their usual activities or even actively living their life,' said Dr

“ME/CFS 可能会造成极大的虚弱，使人们无法进行日常活动，甚至无法积极地生活，”博士说道。

Simon Bock

西蒙·博克

, Project & Market Access Manager of Tiefenbacher Group. '

，Tiefenbacher集团的项目与市场准入经理。'

ReMEdi

showcases our dedication to identifying novel treatment strategies that can alleviate symptoms and improve patient outcomes. We're excited to be working with Lindus Health to help us better understand ME/CFS in our mission to bring a one-of-a-kind treatment to the hands of these patients.'

展示了我们致力于识别能够缓解症状和改善患者预后的新治疗策略。我们很高兴与Lindus Health合作，帮助我们更好地了解ME/CFS，以实现将一种独特疗法交到这些患者手中的使命。

Tiefenbacher and Lindus Health are dedicated to shaping a future in which conditions like ME/CFS are more clearly understood, and patients benefit from safe, effective treatments that significantly enhance their quality of life.

蒂芬巴赫和林达斯健康致力于打造一个未来，让像ME/CFS这样的疾病得到更清晰的理解，患者能够受益于安全有效的治疗，从而显著提升他们的生活质量。

About Lindus Health

关于Lindus健康中心

Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records..

Lindus Health 是一家反传统的合同研究组织，为生命科学先驱者运行速度更快、更可靠的临床试验，从而更快地将突破性治疗带给患者。其实现方式是通过一种使激励措施相一致的商业模式（每项研究固定价格报价，并按里程碑付款）、一支世界级的临床运营团队及其独特的软件平台，以及访问超过4000万份电子健康记录。

Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations.

临床试验是医疗保健领域进步的最大瓶颈。Lindus Health 通过技术驱动和前瞻性临床运营方法，端到端地执行临床研究，消除了这一限制。

To date, Lindus Health has delivered clinical trials across the US, UK, and

迄今为止，Lindus Health已在美国、英国和

Europe

欧洲

to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over

针对一系列疾病，包括糖尿病、哮喘、痤疮、社交焦虑、重度抑郁症、高血压、慢性疲劳综合症和失眠。该公司已经筹集了超过

$80M

8000万美元

from investors including

来自包括投资者在内的

Peter Thiel

彼得·蒂尔

, Balderton, Creandum, Firstminute Capital, and Seedcamp.

，Balderton、Creandum、Firstminute Capital 和 Seedcamp。

About Tiefenbacher Group

关于Tiefenbacher集团

TIEFENBACHER GROUP is a global health care company with a deep sense of purpose: pioneering healthcare to improve patients' lives worldwide. Its entrepreneurial spirit of always challenging the status quo drives the mission to make high-quality pharmaceuticals more affordable, more available, and better than before..

TIEFENBACHER集团是一家全球医疗保健公司，秉承强烈的使命感：开拓医疗保健以改善全球患者的生活。其不断挑战现状的企业家精神推动了使命，即让高品质药物比以往更实惠、更易获得、更好。

Founded in 1963 and 100% family-owned, TIEFENBACHER GROUP employs more than 900 people and provides best-in-class solutions across the entire pharmaceutical value chain—from the initial idea to global market access. The company is engaged in the distribution of raw materials, as well as the development, registration, and manufacturing of affordable, value-added, and innovative medicines.

成立于1963年，家族企业，TIEFENBACHER GROUP拥有900多名员工，为整个制药价值链提供一流解决方案——从最初的概念到全球市场准入。公司致力于原材料的分销，以及开发、注册和生产高性价比、高附加值和创新性的药品。

This includes highly potent oncology drugs and drug-device combinations based on cutting-edge e-health technology..

这包括高效力的肿瘤药物和基于前沿电子健康技术的药械组合。

Press Contact:

媒体联系人:

Jodi Perkins

乔迪·珀金斯

Amendola Communications on behalf of Lindus Health

阿梅ンド拉传播代表林达斯健康

Jperkins@acmarketingpr.com

Phone: 847.508.0877

电话：847.508.0877